Scholarlink

<p>This study investigates the clinical and molecular characteristics of <i>TP53</i>-mutated acute myeloid leukemia (AML), associated with a poor prognosis. A retrospective analysis was conducted on 336 AML patients, focusing on the distinctions between <i>TP53</i>-mutated and non-mutated cases. Our findings reveal that <i>TP53</i> mutations are linked to a higher proportion of leukemic blasts positive for the primitive stem cell markers CD34 and CD41 (with dual positive: 12.5% vs. 1.3%, <i>p</i> &lt; 0.001), suggesting a more stem/progenitor cell-like nature. Patients with <i>TP53</i>-mutated AML exhibited lower white blood cell counts in peripheral blood (<i>p</i> = 0.016) and reduced blast proportion in bone marrow (with a median of 39.6% in <i>TP53</i>-mutated AML and 56.9% in <i>TP53</i> wild-type AML, <i>p</i> = 0.01) at diagnosis. <i>TP53</i>-mutated AML was frequently found in therapy-related AML cases and occurred with fewer concurrent genetic mutations compared to non-mutated AML. In terms of outcomes, <i>TP53</i> mutations corresponded with significantly lower composite complete response rates and shorter overall and progression-free survival. This study highlights the distinct clinical, molecular, and immunophenotypic features of TP53-mutated AML and emphasizes the need for improved therapeutic strategies for this high-risk subtype.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Distinct immunophenotypic and clinical features of TP53-mutated acute myeloid leukemia: high CD34/CD41 expression and lower leukocyte counts

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月21日

查看全文
  • Songyi Park,
  • Sang-A Kim,
  • Sheehyun Kim,
  • Seon Young Kim,
  • Ji Yun Lee,
  • Ja Min Byun,
  • Sang Mee Hwang,
  • Jeong-Ok Lee,
  • Youngil Koh,
  • Junshik Hong,
  • Yoon Hwan Chang,
  • Hyun Kyung Kim,
  • Soo-Mee Bang,
  • Inho Kim,
  • Sung-Soo Yoon,
  • Dong-Yeop Shin

摘要

This study investigates the clinical and molecular characteristics of TP53-mutated acute myeloid leukemia (AML), associated with a poor prognosis. A retrospective analysis was conducted on 336 AML patients, focusing on the distinctions between TP53-mutated and non-mutated cases. Our findings reveal that TP53 mutations are linked to a higher proportion of leukemic blasts positive for the primitive stem cell markers CD34 and CD41 (with dual positive: 12.5% vs. 1.3%, p < 0.001), suggesting a more stem/progenitor cell-like nature. Patients with TP53-mutated AML exhibited lower white blood cell counts in peripheral blood (p = 0.016) and reduced blast proportion in bone marrow (with a median of 39.6% in TP53-mutated AML and 56.9% in TP53 wild-type AML, p = 0.01) at diagnosis. TP53-mutated AML was frequently found in therapy-related AML cases and occurred with fewer concurrent genetic mutations compared to non-mutated AML. In terms of outcomes, TP53 mutations corresponded with significantly lower composite complete response rates and shorter overall and progression-free survival. This study highlights the distinct clinical, molecular, and immunophenotypic features of TP53-mutated AML and emphasizes the need for improved therapeutic strategies for this high-risk subtype.